You have selected a link that will take you away from the amarincorp.com website. Amarin is not responsible for the content of the alternate website. Privacy and security policies of the alternate website may differ from those practiced by Amarin. &nbsp;By clicking on the continue button below, you acknowledge the previous statement and will be taken to the linked site. If you want to remain at this site, select the cancel button. Thank you.

You are about to leave the Amarincorp.com website

The information contained therein is only current as of the date thereof and may not be a complete listing of all documents filed with the Securities Exchange Commission, made public or provided to Amarin shareholders. Amarin expressly disclaims any obligation to review, update or correct these materials after the date thereof. Amarin may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice. Certain statements made on this web site or in materials accessed in or through the investor relations section of our web site are "forward-looking statements," which are subject to risks and uncertainties, and Amarin's actual results may differ (possibly materially) from those indicated in such statements. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. This website is not an offer or a solicitation to buy or sell securities. Please be aware that decisions regarding investments are the responsibility of users. Although this website includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice. This information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates. Information on this website may be revised without any prior notice.

Please click continue below if you belong to the general public. By general public we mean groups that do not work in healthcare, i.e. patients, relatives, job seekers, politicians, investors and other stakeholders.

I belong to to general public

You are about to review presentations, reports, filings and/or other materials regarding Amarin Corporation plc (NASDAQ: AMRN) that contain time-sensitive information.

The content is only for those who work in healthcare. By clicking continue below, you confirm that you work in healthcare. If you do not belong to this group, you can instead select the general option.

I work in healthcare

Select what you are interested in:

Cardiovascular Disease

Our product

Amarin in the UK

Amarin is an innovative global pharmaceutical company committed to providing cost-effective cardiovascular care to high-risk adult cardiovascular patients.

We use innovative science and research methods to develop new, cost-effective treatments for cardiovascular disease. Discover more about our methodology, trials and CV Health from Amarin.

Amarin strives to ensure that our stakeholders have access to appropriate information about our financial growth. Find out more to help you make an independent decision on your investments.

Our mission to help transform the lives of cardiovascular patients across the globe is only just beginning and if you share our passion for innovation and improving patient care, we want to hear from you.

Search